March 10, 2008 13:00 ET

Strategic Alliances and Sourcing for Pharma Covered at iiBIG Boston Forum, March 25-26th

NEW YORK, NY--(Marketwire - March 10, 2008) - Outsourcing collaborations at every stage of discovery and development are helping to meet these growing demands, and are driving innovation and growth in the industry. Business relationships in outsourcing must manage priorities, costs, timelines and intellectual property.

At iiBIG's 2008 BioPharma Outsourcing: Partnerships with CROs and Other Service Providers forum, scheduled for March 25-26, 2008 in Boston, MA, will review who is doing what -- and what is next -- in this exciting area of partnership and collaboration.

In the scheduled panel session "The Evolution of Complex Strategic Alliances and Sourcing -- Where Big Pharma is Headed," discussion will cover outsourcing and offshoring as becoming increasingly important to large pharmaceuticals in various phases of drug development, discovery, and strategic sourcing. Key industry leaders on this panel include Steven Tregay, Managing Director, Novartis Option Fund; Diana M. Galer, VP, Strategic Management Group, Pfizer Global Research & Development; and Christine T. Fischette, Ph.D., President, Enzo Therapeutics.

This year's agenda will also cover:

--  The Business of Outsourcing: Strategic Innovation in Biopharma
--  Outsourcing Discovery Chemistry: What Makes It Work?
--  Identifying the Right CRO and Shepherding a Product in Preclinical
--  Going Global: Understanding Diverse Alliances, Partnerships and
    Outsourcing Platforms Investment and M&A Outlook for the BioPharma Industry
--  Opportunities for Companies with Outsourcing Business Models
--  Creating an Unified Drug Safety and Pharmacovigilance Environment
--  Protein Bioanalysis: Building a Partnership from the Ground Up

For complete agenda and speaker roster:

For more conference information and to register:
Phone: 212-300-2523

Contact Information